The Commons

What happens when hospitals stop being simply consumers of medical technology and increasingly become creators of it?

In this episode of The Commons, host Thomas Osha sits down with Dr. Frank Rybicki, Professor and Chair of Radiology at the University of Arizona College of Medicine–Phoenix, for a fascinating look at how artificial intelligence, advanced imaging, and medical 3D printing are moving directly into clinical workflows.

Dr. Rybicki describes how patient-specific anatomical models and surgical guides can now be created inside health systems, sometimes reducing turnaround from days to hours. These tools can help physicians plan complex procedures, improve communication with patients, and even guide surgeons during an operation.

AI is accelerating that transformation. Dr. Rybicki explains how AI-assisted imaging can dramatically reduce laborious image-processing tasks, help personalize risk assessment, and augment rather than simply replace human clinical judgment.

The implications extend beyond major academic medical centers. From AI-guided handheld ultrasound to lower-cost, focused AI tools, the same technologies could ultimately bring sophisticated diagnostic capabilities to rural and underserved communities.

The conversation raises a larger question about the future of healthcare innovation: What happens when the hospital itself becomes a platform where clinicians, engineers, data scientists, and researchers can rapidly create and deploy solutions around the needs of individual patients?

It's a glimpse of a future of medicine that is more personalized, more immediate—and potentially more human.

For decades, economic development followed a familiar playbook: recruit a company, offer incentives, count the jobs, and move on to the next deal.

That model is changing.

In this episode of The Commons, recorded live at BIO 2026, host Thomas Osha sits down with Chris Mackay, President and CEO of the Greater Phoenix Economic Council, to explore a different model, one built around ecosystems rather than transactions.

Mackay describes how Greater Phoenix has evolved from an economy heavily dependent on growth into an increasingly diversified innovation economy spanning semiconductors, advanced manufacturing, bioscience, AI, quantum technologies, and healthcare. At the center of that transformation is something harder to replicate than financial incentives: a culture of regional collaboration.

Their conversation explores why universities, companies, government, entrepreneurs, economic developers, and investors increasingly need to operate as partners; why workforce has become fundamental innovation infrastructure; and how Phoenix's 22 cities have learned to practice what Mackay calls "coop-petition" - competing locally while advancing the region together.

The result is a provocative new framework for economic development: decide what kind of economy you want to create, work backward to build the talent, infrastructure, partnerships and places it requires, and then stay committed long enough for the ecosystem to take root.

For anyone interested in cities, universities, innovation districts, talent or regional economic competitiveness, this is a conversation about how places position themselves to win.

Scientific breakthroughs get the attention. But between a promising discovery and a product that reaches patients lies another challenge entirely: can you actually make it - reliably, affordably, and at scale?

In this episode of The Commons, host Thomas Osha sits down with Behrad Vahidi of SCHOTT MINIFAB to explore the often-overlooked world of microfluidics, diagnostic consumables, and design for manufacturing.

Vahidi explains how lab-on-a-chip technologies can move complex testing out of centralized laboratories and closer to patients while reducing reagent use, lowering costs, and increasing reproducibility. But achieving that promise requires thinking about manufacturing much earlier than many innovators realize.

Their conversation explores why a prototype that works ten times may fail when produced a million times, how startups can avoid costly redesigns by incorporating manufacturability from the beginning, and the role sophisticated pilot manufacturing infrastructure can play in helping young companies reach clinical validation without enormous upfront capital investment.

The discussion also turns to university commercialization and an important question: Should manufacturing expertise have a seat at the table much earlier when researchers begin translating discoveries into companies?

It's a fascinating look at the largely invisible engineering and infrastructure that turns promising science into products capable of changing lives.

At conferences like BIO, breakthrough science commands the spotlight. But behind every successful healthcare company is another story; one of founders, investors, mentors, and the difficult journey from promising research to investable business.

In this episode of The Commons, host Thomas Osha welcomes Anne Mazet, Chief-of-Staff at Xcellerant Ventures, for a candid conversation about what separates great science from companies capable of attracting investment and creating lasting impact.

Anne shares why venture investors often place as much emphasis on founders as they do on technology, why researchers should engage investors earlier than they think, and how coachability, strategic planning, and the willingness to build the right leadership team can dramatically improve a company's odds of success.

The discussion also explores Phoenix's collaborative innovation ecosystem, the evolving venture capital landscape, and Xcellerant's innovative Jetstream Venture Fund, which is expanding access to venture investing through a more inclusive investment model. Along the way, Anne offers practical advice for university spinouts, startup founders, and anyone navigating the challenging path from laboratory discovery to commercialization.

Whether you're building a startup, supporting technology transfer, or simply curious about how healthcare innovation reaches the marketplace, this episode provides valuable insights into the people, partnerships, and investment decisions that turn promising ideas into successful companies.

The promise of cell and gene therapy is extraordinary. But between a scientific breakthrough and a patient receiving a potentially life-changing treatment lies one of the most complex, precise, and largely invisible networks in healthcare.

Recorded live from the BIO International Convention, host Tom Osha sits down with Melissa Marlow, Vice President of Clinical Services and Biotherapies Lab at Vitalant, to explore the infrastructure behind advanced cell therapies and why that infrastructure is critical to expanding patient access.

With roots stretching back to a Phoenix blood bank founded more than 80 years ago, Vitalant has built a national network capable of supporting the collection, handling, storage, and delivery of increasingly complex therapies. Melissa takes us behind the scenes of that network, where cells may need to be stored below -150 degrees Celsius, timing is measured in critical windows, and a single patient therapy can touch more than 100 people on its journey from collection to manufacturing and back to the patient.

Unlike a traditional pharmaceutical product, many of today's cell therapies are autologous, created from a patient's own cells specifically for that patient. There is no replacement batch sitting on a shelf. Every product is truly one of a kind.

Tom and Melissa also discuss the next frontier: moving therapies like CAR-T beyond treatments of last resort and expanding access to patients outside the nation's largest academic medical centers.

It's a conversation about science, logistics, culture, and the remarkable human infrastructure required to turn breakthrough medicine into patient care.

Scientific discovery is only the beginning. The real challenge is transforming breakthrough research into products and companies that improve lives.

Recorded live at BIO, this episode of The Commons features Leith Martin, Executive Director of the Pacific Desert Innovation Hub for NSF I-Corps, a program that is reshaping how researchers approach innovation and entrepreneurship across the Southwest.  He is also Executive Director of the Troesh Center for Entrepreneurship and Innovation in the Lee Business School at UNLV, where he oversees entrepreneurship programs and the academic entrepreneurship curriculum.

Originally developed by the National Science Foundation, I-Corps has helped thousands of scientists and engineers learn a deceptively simple lesson: before building a company, you have to deeply understand the problem you're trying to solve. Through customer discovery, market validation, and entrepreneurial training, researchers learn to test assumptions, engage potential users, and refine their ideas long before launching a startup.

In our conversation, Leith explains why some of the world's most promising technologies never reach the marketplace, how I-Corps is helping bridge the gap between discovery and commercialization, and why entrepreneurial thinking has become an essential skill for today's research community. We also discuss the role programs like the Pacific Desert Innovation Hub play in strengthening regional innovation ecosystems and accelerating the translation of research into economic and societal impact.

Whether you're a scientist, entrepreneur, investor, or simply interested in how great ideas become real-world solutions, this conversation offers valuable lessons about the future of innovation.

Phoenix is one of the most closely watched innovation markets in the country, but growth at this scale does not happen by accident. In this episode of The Commons, recorded live as part of our special series spotlighting Arizona’s bioscience and innovation economy, Tom Osha sits down with Ryan Touhill, Director of Economic Development for the City of Phoenix.

Together, they explore how Phoenix is translating long-term vision into measurable momentum across life sciences, advanced industries, entrepreneurship, and place-based economic development. Ryan shares how the city is thinking beyond traditional business attraction, focusing instead on building the conditions that allow innovation ecosystems to thrive over time.

The conversation examines the role of public leadership in creating environments where research institutions, startups, established industry, and developers can align around shared growth. Ryan also reflects on Phoenix’s emergence as a national bioscience hub, the importance of strategic partnerships, and how the city is investing in the infrastructure, talent, and community assets required to sustain innovation.

From district-scale development to economic competitiveness, this episode offers a candid look at how cities can move from ambition to execution, and why Phoenix’s next chapter may be even more consequential than its last.

Our special BIO series begins with a conversation that challenges how we think about health, disease, and discovery.

In this episode of The Commons, we sit down with Melissa Herbst-Kralovetz, professor at the University of Arizona College of Medicine – Phoenix and director of the Translational Women’s Health Research Program, whose work is helping uncover the complex relationship between the microbiome, immunity, and women’s health outcomes. Her research focuses on how microbial communities and host biology interact in the female reproductive tract — with implications for infection, cancer prevention, diagnostics, and earlier intervention. 

Together, we explore one of the most fascinating frontiers in bioscience: how understanding the body’s hidden ecosystems may transform the future of medicine. We discuss the evolution of translational science, why women’s health represents one of the most important opportunities in modern research, and what it takes to move discoveries from the laboratory into meaningful impact for patients. 

Recorded live during BIO, this conversation also reflects a broader story unfolding across Arizona — where researchers, institutions, and innovators are building an ecosystem designed to accelerate discovery and improve health outcomes at scale.

This special series of The Commons comes to you live from BIO, where the world’s leading biotechnology companies, researchers, investors, and ecosystem builders gather to shape what’s next in health and life sciences.

Across a series of conversations, we explore a bigger question: What does it take to build a world-class bioscience ecosystem?

From breakthrough therapeutics and emerging startups to commercialization strategies, talent pipelines, and statewide collaboration, this series highlights the people and ideas helping define Arizona’s next chapter in innovation.

Featuring leaders from research institutions, foundations, startups, and industry, these discussions examine how discoveries move from lab to market, how regions compete on a global stage, and why the future of bioscience depends as much on connection and place as it does on scientific excellence.

Throughout the series, we spotlight Arizona’s growing momentum, from translational research and entrepreneurship to the partnerships and infrastructure needed to accelerate impact and improve health outcomes.

Whether you are an entrepreneur, researcher, policymaker, investor, or simply curious about where the future of health is heading, these conversations offer a front-row seat to the ideas and relationships shaping tomorrow.

When people talk about Arizona's emergence as a bioscience leader, the conversation often focuses on Phoenix. But the state's success story is much larger than any single city.

In this episode of The Commons, host Thomas Osha welcomes Mary O'Reilly of the Flinn Foundation for a discussion about the Arizona Bioscience Roadmap and the unique role it has played in advancing innovation and economic development across the entire state.

For more than two decades, the Roadmap has provided a shared framework for strengthening Arizona's bioscience sector through strategic investments, collaborative partnerships, talent development, research growth, and commercialization. Unlike many economic development initiatives that focus on a single metropolitan area, Arizona's approach has sought to connect assets and opportunities across the state, aligning universities, healthcare systems, research institutions, entrepreneurs, industry leaders, and policymakers around a common vision.

In this conversation, O'Reilly explores how the Roadmap was developed, why it has endured through changing economic and political environments, and how it continues to serve as a catalyst for statewide collaboration. She discusses the measurable impact the strategy has had on research capacity, workforce development, startup formation, healthcare innovation, and Arizona's growing reputation as a center for bioscience and technology-driven growth.

The discussion also examines a broader question facing regions throughout the world: how can communities sustain a long-term innovation strategy that extends beyond individual projects, leaders, or election cycles?

As The Commons prepares to broadcast from the Arizona Pavilion at the BIO International Convention in San Diego, this episode offers an important perspective on the value of statewide thinking and the power of patient, coordinated leadership.